| Literature DB >> 35518883 |
Yu-Dan Mei1,2, Hai-Bo Li3, Qian-Qian Pang1, Ting Li1, Da-Bo Pan1, Yi Dai1, Da-Peng Qin1, He Meng2, Xin-Sheng Yao1, Yang Yu1.
Abstract
Lonimacranaldes A and B (1 and 2), along with one biogenetically related intermediate, lonimacranalde C (3), were isolated from the flower buds of Lonicera macranthoides. Characterized by an iridoid structure and an additional C-6 unit with an aldehyde group, compounds 1 and 2 are the first examples of hybrid iridoids possessing an unexpected 6/5/6 fused tricyclic ring system, while compound 3 serves as an important precursor for their generation. The structures of lonimacranaldes A-C (1-3) were revealed by extensive spectroscopic and X-ray diffraction analyses. A plausible biogenetic pathway for them was proposed. Compound 3 showed anti-inflammatory activities by inhibiting the production of IL-6 on LPS-induced RAW 264.7 cells with an IC50 value of 6.33 μM. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35518883 PMCID: PMC9066900 DOI: 10.1039/c9ra04029c
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Chemical structures of compounds 1–3.
Fig. 2Key 1H–1H COSY, HMBC, and ROESY correlations of 1–3.
Fig. 3Key NOESY correlations and X-ray crystallographic analysis of 1.
Fig. 4Key NOESY correlations of 2.
Fig. 5Experimental CD spectra of 1 and 2.
1H NMR and 13C NMR data for compounds 1–3a
| No. | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 98.6 | 5.21, d (7.1) | 97.2 | 5.35, d (5.9) | 97.7 | 5.55, d, (5.6) |
| 3 | 153.5 | 7.48, d (1.2) | 153.4 | 7.49, d (1.1) | 153.9 | 7.52, d (1.1) |
| 4 | 112.2 | 113.0 | 110.8 | |||
| 5 | 35.2 | 2.68, q (7.8) | 33.6 | 3.06, ddd (8.8, 8.0, 4.3) | 33.5 | 3.04 |
| 6 | 38.9 | 2.00, ddd (13.0, 6.7, 4.4) | 37.8 | 2.23 | 30.2 | 2.50, ddd (15.2, 8.0, 7.0) |
| 1.85 | 1.68, ddd (13.3, 10.5, 8.8) | 2.99 ddd (15.2, 7.0, 7.0) | ||||
| 7 | 35.7 | 2.89 | 34.7 | 2.79, q (9.0) | 155.5 | 6.63, t (7.0) |
| 8 | 38.4 | 2.47 | 40.4 | 2.25 | 135.4 | 5.77, ddd (17.1, 10.4, 9.0) |
| 9 | 46.1 | 1.94, td (7.8, 4.8) | 48.8 | 2.09, ddd (8.0, 5.9, 2.5) | 45.4 | 2.70, dt (9.0, 5.6) |
| 10 | 32.1 | 1.88 | 33.7 | 1.88, ddd (13.0, 5.0, 4.6) | 120.0 | 5.27, m |
| 1.40, ddd (13.6, 9.1, 4.6) | 1.13, ddd (13.0, 13.0, 11.1) | |||||
| 11 | 170.9 | 170.9 | 170.4 | |||
| 1′ | 196.4 | 9.38, s | 196.5 | 9.40, s | 197.1 | 9.33, s |
| 2′ | 145.1 | 145.3 | 145.6 | |||
| 3′ | 158.1 | 6.93, d (2.8) | 157.0 | 6.80, d (2.0) | 24.8 | 2.21 |
| 4′ | 36.1 | 2.30 | 40.0 | 2.30 | 32.0 | 1.30 |
| 5′ | 28.7 | 1.57, ddq (14.0, 14.0, 7.4) | 28.8 | 1.59, ddq (14.0, 14.0, 7.4) | 23.8 | 1.30 |
| 1.48, ddq (14.0, 14.0, 7.4) | 1.51, ddq (14.0, 14.0, 7.4) | |||||
| 6′ | 11.8 | 1.05, t (7.4) | 11.5 | 1.03, t (7.4) | 14.2 | 0.91, t (7.0) |
| 1′′ | 100.3 | 4.72, d (7.8) | 100.3 | 4.67, d (7.9) | 100.2 | 4.69, d (7.9) |
| 2′′ | 74.8 | 3.21, dd (9.0, 7.8) | 74.7 | 3.21, dd (9.2, 7.9) | 74.7 | 3.20, dd (9.2, 7.9) |
| 3′′ | 78.0 | 3.39, t (8.7) | 78.0 | 3.38, dd (9.2, 8.7) | 78.0 | 3.37, dd (9.2, 8.9) |
| 4′′ | 71.6 | 3.29 | 71.6 | 3.29 | 71.6 | 3.28, dd (9.7, 8.9) |
| 5′′ | 78.4 | 3.30 | 78.3 | 3.30 | 78.4 | 3.31 |
| 6′′ | 62.8 | 3.90, dd (11.9, 2.1) | 62.7 | 3.86, dd (11.9, 1.9) | 62.7 | 3.89, dd (11.9, 2.2) |
| 3.67, dd (11.9, 5.9) | 3.65, dd (11.9, 5.4) | 3.66, dd (11.8, 5.8) | ||||
Recorded at 600 (1H) and 150 MHz (13C) in CD3OD. Multiplets or overlapped signals are reported without designating multiplicity.
Scheme 1Plausible biosynthetic pathway of 1, 2 and 3.
Fig. 6Effect of compound 3 on IL-6 production in LPS-stimulated RAW 264.7 cells.